Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.
Wood C, Lyniv L, Isaacs JM, Kaufman JM, Oduah EI, Clarke J, Crawford J, Stinchcombe T, Tong BC, Wang X, Gu L, Wigle D, Dragnev KH, Antonia SJ, Weinhold K, Ready N.
Wood C, et al. Among authors: wang x.
J Immunother Cancer. 2025 Feb 4;13(2):e010395. doi: 10.1136/jitc-2024-010395.
J Immunother Cancer. 2025.
PMID: 39904561
Clinical Trial.